ArticleBJA open2026
The association of estimated citrate load with frozen plasma versus four-factor prothrombin complex concentrate for coagulopathy after cardiac surgery: a
Article in BJA open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05523297 (Prospective, Multicenter, Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Bleeding Adult Cardiac Surgical Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Multicenter, Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Bleeding Adult Cardiac Surgical Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Frozen plasma (FP) is the standard haemostatic therapy after cardiopulmonary bypass, but recent trials indicate that FP is inferior to four-factor prothrombin complex concentrate (PCC). Citrate content may contribute to this difference. We compared estimated citrate exposure between patients receiving FP and those receiving PCC and explored its association with postoperative bleeding. Methods: This Results: In the FP group, total estimated citrate exposure was substantially higher, and the median per-patient estimated citrate load was approximately six-fold greater at 12-24 h. Administration of citrate-containing products continued through 8 h in patients receiving FP but was largely confined to the first 2 h in patients receiving PCC. Across all quartiles of estimated 12-h citrate load, patients treated with FP had higher estimated citrate exposure and chest tube drainage; patients treated with PCC in the highest quartile exhibited drainage volumes similar to those of patients treated with FP in the third quartile. Conclusions: This exploratory, hypothesis-generating analysis demonstrated markedly higher estimated citrate exposure with FP than PCC. Although causality cannot be established without direct citrate measurement, FP was associated with higher estimated citrate load and more variable chest tube drainage. Factor concentrates may reduce this burden, warranting further mechanistic investigation.ClinicalTrials.gov identifier: NCT05523297; https://clinicaltrials.gov/study/NCT05523297?term=NCT05523297&rank=1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.